Notably, BET bromodomain inhibition has been utilized in concert with TK inhibitors to overcome resistance-driving mutations in leukemia, and combinations of FLT3 and BET bromodomain inhibitors delivered as separate compounds are being explored as therapies [16–18]. Here, DNER is linked to leukemia.